
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp is well-positioned for growth due to its promising vaccine candidates, particularly the shingles vaccine, which demonstrates vaccine response rates (VRR) comparable to Shingrix with significantly better tolerability. The company leverages its Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses, reinforcing the potential for its product candidates across various cancer indications and its established HEPLISAV-B vaccine. Additionally, the favorable results in immunogenicity and tolerability for its products indicate a strong competitive advantage, which is expected to drive continued revenue growth primarily from the sale of its CpG 1018 product and HEPLISAV-B.
Bears say
Dynavax Technologies faces a negative outlook primarily due to the inherent risks associated with its clinical development pipeline, specifically the potential failure of future candidates to meet efficacy or safety standards, which could hinder approval and commercialization. Additionally, the company may struggle to effectively commercialize its products in a competitive market landscape, which could undermine its revenue generation capabilities. Lastly, uncertainties regarding the ability to secure acceptable partnership terms for its candidates further elevate the risks surrounding the successful launch and market penetration of its proprietary therapies.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares